Could synthetic macrocyclic peptides be the Next Big Thing to lift biotech? A potential $1.5 billion deal suggests things are ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma.Results of the ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [ NCT05171647] study showing Lunsumio ® (mosunetuzumab-axgb) administered ...

Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel ...

Explore the evolving RVO treatment landscape from anti-VEGF breakthroughs to pipeline innovations addressing unmet needs in efficacy, safety, and dosing burden. Retinal Vein Occlusion care is entering ...

CAMBRIDGE, Mass. - Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company with a market capitalization of $5.4 billion, has appointed Christy Oliger to its Board of Directors ...

Company News Published 06/18/2025, 05:00 PM 0 Nuvalent appoints former Genentech oncology executive to board NUVL 0.70% ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) investigating Venclexta ® (venetoclax ...